ArticleClinical cancer research : an official journal of the American Association for Cancer Research2009
Development and characterization of a novel in vivo model of carcinoid syndrome.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388).Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Selective right heart valve remodelling in a mouse model of carcinoid disease revealed by high-resolution episcopic microscopy.Scientific reports · 2025Article
- Does Telotristat Have a Role in Preventing Carcinoid Heart Disease?International journal of molecular sciences · 2024Article
- Carcinoid Syndrome: Preclinical Models and Future Therapeutic Strategies.International journal of molecular sciences · 2023Review
- Specific Urinary Metabolites in Malignant Melanoma.Medicina (Kaunas, Lithuania) · 2019Article
- Carcinoid-syndrome: recent advances, current status and controversies.Current opinion in endocrinology, diabetes, and obesity · 2018Review
- Complications from carcinoid syndrome: review of the current evidence.Ecancermedicalscience · 2016Review
- A mechanistic role for the chromatin modulator, NAP1L1, in pancreatic neuroendocrine neoplasm proliferation and metastases.Epigenetics & chromatin · 2014Article
- Dual inhibition of PI3K and mTOR signaling pathways decreases human pancreatic neuroendocrine tumor metastatic progression.Pancreas · 2014Article
- Generation of Pet1210-Cre transgenic mouse line reveals non-serotonergic expression domains of Pet1 both in CNS and periphery.PloS one · 2014Article
- Serotonin and the 5-HT7 receptor: the link between hepatocytes, IGF-1 and small intestinal neuroendocrine tumors.Cancer science · 2013Article
- Article
- The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study.PloS one · 2013Article
- The effect of PTEN on serotonin synthesis and secretion from the carcinoid cell line BON.Anticancer research · 2011Article
- VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis.International journal of cancer · 2011Article
- Serotonin reverts age-related capillarization and failure of regeneration in the liver through a VEGF-dependent pathway.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
- An analysis of trends and growth factor receptor expression of GI carcinoid tumors.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
purposeCarcinoid syndrome, characterized by flushing, diarrhea, and valvular heart disease, can occur following carcinoid tumor metastasis to the liver and systemic release of bioactive hormones into the systemic circulation. Treatment of this devastating disease is hampered by the lack of an in vivo model that recapitulates the clinical syndrome. EXPERIMENTAL
designHere, we have injected BON cells, a novel human carcinoid cell line established in our laboratory, into the spleens of athymic nude mice to establish liver metastases.
resultsThe majority of mice injected intrasplenically with BON cells developed significant increases in plasma serotonin and urine 5-hydroxyindoleacetic acid, and several mice exhibited mesenteric fibrosis, diarrhea, and fibrotic cardiac valvular disease reminiscent of carcinoid syndrome by both echocardiographic and histopathologic evaluation. Mice pretreated with octreotide, a long-acting somatostatin analogue, or bevacizumab, a vascular endothelial growth factor inhibitor, developed fewer liver metastases and manifestations of carcinoid syndrome, including valvular heart disease.
conclusionWe have provided an important in vivo model to further delineate novel treatment modalities for carcinoid syndrome that will also be useful to elucidate the factors contributing to the sequelae of carcinoid disease (e.g., mesenteric fibrosis and valvular heart disease).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.